What is NGX Bio?
Founded by Stanford academics, NGX Bio emerged as a specialized marketplace designed to streamline the complex process of organism sequencing. The platform functions as a comparative shopper and quality-control arbiter, aggregating demand to secure favorable pricing and reliable turnaround times for researchers. Following its 2019 acquisition by Admera Health, the organization has significantly broadened its operational scope. It now provides a comprehensive suite of Next-Generation Sequencing (NGS) products, services, and solutions, supported by an expansive network of technical partners. This integration allows NGX Bio to manage the entire lifecycle of genomic projects, from initial sample preparation to advanced data management and bioinformatics analysis.
How much funding has NGX Bio raised?
NGX Bio has raised a total of $3M across 1 funding round:
Private Equity
$3M
Private Equity (2017): $3M with participation from 180 Degree Capital Corp, Lateral Capital, Band of Angels, Third Kind Venture Capital, and Berkeley Angel Network
Key Investors in NGX Bio
180 Degree Capital Corp
A firm specializing in identifying and investing in publicly traded micro-cap stocks, employing a constructive activist approach to unlock hidden value.
Lateral Capital
A mission-driven venture fund that partners with visionary entrepreneurs building essential digital infrastructure, offering both debt and equity support.
Band of Angels
Silicon Valley's oldest angel investment group, consisting of high-tech executives who provide funding, mentoring, and guidance to seed-stage startups.
What's next for NGX Bio?
With the backing of major strategic investment, NGX Bio is well-positioned to scale its infrastructure and deepen its integration within the Admera Health ecosystem. The focus moving forward will likely center on enhancing the scalability of its NGS-based solutions and expanding its footprint in the clinical and research genomics markets. By leveraging its established network of sequencing facilities, the company is poised to capitalize on the growing demand for high-throughput, accurate genomic data, further cementing its status as a vital component of the modern biotechnology research landscape.
See full NGX Bio company page
